Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mosaic Biomedicals
Barcelona, Catalonia, Spain
- Ownership
- Private
- Development stage
- Other
01
Overview
Mosaic Biomedicals developed MSC-1, a first-in-class monoclonal antibody targeting leukemia inhibitory factor (LIF) to inhibit tumor progression and cancer stem cells in solid tumors; following its merger with Northern Biologics and option deal with Celgene, MSC-1 advanced into multi-center Phase 1 clinical trials in Europe and the United States beginning in 2017.[2][3]
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Northern Biologics[2]Celgene[2]Versant Ventures (strategic investor)[2]Vall d'Hebron Institute of Oncology (spin-off relationship)[2][3]Vall d'Hebron Research Institute (VHIR spin-off relationship)[1][2]
Beyond the preview
Go deeper on Mosaic Biomedicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mosaic Biomedicals.